thallous (tl201) chloride injection 37mbq/ml injekční roztok
curium netherlands b.v., petten array - 9673 chlorid thallnÝ-(201tl) - injekční roztok - 37mbq/ml - chlorid thallnÝ-(201tl)
thallium aceticum 3ch-200ch granule
boiron, messimy array - 50978 thallosi acetas - dilutio homeopathica - granule - 3ch-200ch - homeopatika (ČeskÁ atc skupina)
gallium(ga 67)citrate injection 37mbq/ml injekční roztok
curium netherlands b.v., petten array - 4847 gallium-(67ga)-citrÁt - injekční roztok - 37mbq/ml - gallium-(67ga)-citrÁt
allium cepa 3ch-30ch granule
boiron, messimy array - 50074 allium cepa - dilutio homeopathica - granule - 3ch-30ch - homeopatika (ČeskÁ atc skupina)
allium sativum 3k-10mk granule
boiron, messimy array - 50996 allium sativum - dilutio homeopathica - granule - 3k-10mk - homeopatika (ČeskÁ atc skupina)
corallium rubrum 2ch-200ch granule
boiron, messimy array - 50547 corallium rubrum - dilutio homeopathica - granule - 2ch-200ch - homeopatika (ČeskÁ atc skupina)
galliapharm 0,74-1,85gbq radionuklidový generátor
eckert & ziegler radiopharma gmbh, berlin array - 21430 chlorid germaniČitÝ-(68ge); 21261 chlorid gallitÝ-(68ga) - radionuklidový generátor - 0,74-1,85gbq - jinÁ diagnostickÁ radiofarmaka
coryzalia obalená tableta
boiron, messimy array - 50406 allium cepa 3 c; 50405 belladonna 3 c; 50407 sabadilla 3 c; 50410 kalii dichromas 3 c; 50408 gelsemium 3 c; 50409 pulsatilla pratensis 3 c - obalená tableta - homeopatika (ČeskÁ atc skupina)
drosetux neo sirup
boiron, messimy array - 50441 arnica montana 4 c; 50414 belladonna 4 c; 51329 cina 4 c; 52088 dactylopius coccus 5 c; 52056 corallium rubrum 4 c; 51246 cuprum metallicum 5 c; 52057 drosera 4 c; 51368 ferrum phosphoricum 5c; 52058 ipecacuanha 4 c; 50428 solidago virga aurea 3 d - sirup - homeopatika (ČeskÁ atc skupina)
locametz
novartis europharm limited - gozetotide - radionuklidové zobrazování - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.